Premium
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
Author(s) -
Leiter Lawrence A.,
Bain Stephen C.,
Bhatt Deepak L.,
Buse John B.,
Mazer C. David,
Pratley Richard E.,
Rasmussen Søren,
Ripa Maria Sejersten,
Vrazic Hrvoje,
Verma Subodh
Publication year - 2020
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.14079
Subject(s) - semaglutide , liraglutide , mace , medicine , diabetic nephropathy , nephropathy , blood pressure , type 2 diabetes , diabetes mellitus , dulaglutide , endocrinology , placebo , cardiology , alternative medicine , pathology , myocardial infarction , conventional pci
It is unknown if the cardioprotective and renal effects of glucagon‐like peptide‐1 receptor agonists are consistent across blood pressure (BP) categories in patients with type 2 diabetes and at high risk of cardiovascular events. Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional hazards model (treatment and subgroup as factors; adjusted for cardiorenal risk factors). Data from the two trials were analysed separately. In the LEADER and SUSTAIN 6 trials, the prevalence of stage 1 hypertension was 30% and 31%, respectively, and of stage 2 hypertension 41% and 43%, respectively. There was no statistical heterogeneity across the BP categories for the effects of liraglutide ( P = .06 for MACE; P = .14 for nephropathy) or semaglutide ( P = .40 for MACE; P = .27 for nephropathy) versus placebo. This implies that liraglutide and semaglutide may be beneficial for patients with type 2 diabetes, irrespective of their baseline BP.